Genetic predisposition to myocardial infarction showed no significant causal effect on the risk of prostate cancer (OR 1.000, 95% CI 0.995–1.004), bladder cancer (OR 1.000, 95% CI 0.999–1.002), or malignant neoplasm of kidney (OR 0.989, 95% CI 0.866–1.130).
Does genetic predisposition to myocardial infarction causally increase the risk of prostate, bladder, or kidney cancer in individuals of European ancestry?
Genetic evidence does not support a bidirectional causal relationship between myocardial infarction and urinary system cancers, suggesting that observed epidemiological associations are likely due to shared risk factors or confounding.
Effect estimate: OR 1.000 for prostate cancer (discovery cohort), 0.964 for prostate cancer (validation cohort), 1.000 for bladder cancer, 0.989 to 1.060 for malignant neoplasm of kidney (95% CI 95% CI 0.995–1.004 for PCa discovery, 0.904–1.027 for PCa validation, 0.999–1.002 for BCa discovery, 0.998–1.000 for MRN validation)
p-value: p=>0.05 for all analyses
Background: Observational studies have suggested potential associations between myocardial infarction (MI) and cancer risk, but the causal nature of these relationships remains unclear due to confounding factors and reverse causation. We aimed to investigate the bidirectional causal relationships between MI and urinary system cancers using genetic instruments. Methods: We conducted a two-sample Mendelian randomization (MR) analysis using summary statistics from large-scale genome-wide association studies. Genetic variants associated with MI were used as instrumental variables (n = 19 SNPs for prostate cancer PCa and malignant neoplasm of kidney MRN, n = 6 SNPs for bladder cancer, n = 21 SNPs for bladder cancer BCa validation). We examined the causal effects of MI on PCa, BCa, and MRN risk, as well as reverse causation. Multiple MR methods were employed, including inverse variance weighted (IVW), MR-Egger, weighted median, and weighted mode approaches. Both discovery and validation datasets were analyzed to ensure robustness. Results: Forward MR analysis revealed no significant causal effect of MI on urinary system cancer risk across all examined malignancies. For PCa, the odds ratios (ORs) ranged from 0.964 to 1.007 across different methods and datasets (all p > 0.05). Similarly, MI showed no causal association with BCa risk (OR = 1.000, 95% CI: 0.999–1.002 in discovery cohort; OR = 1.000, 95% CI: 1.000–1.001 in validation cohort) or MRN risk (OR = 0.989–1.060 across methods in discovery cohort). Reverse MR analysis demonstrated no significant causal effects of PCa or kidney malignancy on MI risk, with ORs ranging from 0.250 to 1.200 (all p > 0.05). Sensitivity analyses confirmed the absence of pleiotropy and heterogeneity. Conclusion: Our genetic evidence does not support causal relationships between MI and urinary system cancers in either direction. The observed associations in epidemiological studies may be attributed to shared risk factors, treatment effects, or residual confounding rather than direct causal mechanisms. These findings have important implications for cancer surveillance strategies in MI patients and understanding cardio-oncology interactions.
Zhang et al. (2026) studied Individuals of European ancestry with genetic data on myocardial infarction and urinary system cancers (prostate cancer, bladder cancer, malignant neoplasm of kidney). Genetic predisposition to myocardial infarction vs. No genetic predisposition to myocardial infarction was evaluated on Causal effect of myocardial infarction on urinary system cancer risk (prostate cancer, bladder cancer, malignant neoplasm of kidney) assessed by odds ratio from Mendelian randomization analyses (OR 1.000 for prostate cancer (discovery cohort), 0.964 for prostate cancer (validation cohort), 1.000 for bladder cancer, 0.989 to 1.060 for malignant neoplasm of kidney, 95% CI 95% CI 0.995–1.004 for PCa discovery, 0.904–1.027 for PCa validation, 0.999–1.002 for BCa discovery, 0.998–1.000 for MRN validation, p=>0.05 for all analyses). Genetic predisposition to myocardial infarction showed no significant causal effect on the risk of prostate cancer (OR 1.000, 95% CI 0.995–1.004), bladder cancer (OR 1.000, 95% CI 0.999–1.002), or malignant neoplasm of kidney (OR 0.989, 95% CI 0.866–1.130).